Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.40), $0.02 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.17 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Gogoro CFO retires, Jacky Lee named principal financial officer
• Best Buy (BBY) PT Raised to $85 at Wedbush ahead of earnings